broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K87782578-001-01-4 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.961845 | -0.397941 | -0.10282 | 0.974759 | 0.675511 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000991 |
BRD-K87909389-003-03-4 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.063358 | 0.403848 | 0.275952 | 0.467556 | 0.032188 | 0.04502 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000991 |
BRD-K88510285-001-17-8 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.280933 | 3.759739 | 0.615386 | 0.697278 | 0.042092 | 0.052423 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000991 |
BRD-K89014967-001-04-3 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.711114 | 0.432665 | 0.044326 | 0.816202 | 0.013956 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000991 |
BRD-K92441787-001-04-1 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.859085 | -1.150759 | -0.181561 | 0.932295 | 0.064524 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000991 |
BRD-K95142244-001-01-5 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.005779 | 0.010996 | -0.030255 | 1 | 0.000248 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000991 |
BRD-K96123349-236-02-8 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.477619 | 0.701229 | 0.050659 | 1 | 0.839341 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000991 |
BRD-K98572433-001-02-9 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.935159 | -2.175212 | -0.112 | 0.964029 | 0.132895 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000991 |
BRD-K99113996-001-02-0 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 4.940129 | 1.27769 | -0.012932 | 1 | 444,678.149571 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000991 |
BRD-K99616396-001-05-1 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.104605 | 0.033504 | -0.010497 | 1 | 0.040713 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000991 |
BRD-K99749624-001-07-0 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 0.944259 | -0.010468 | -0.102356 | 0.972054 | 0.131189 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000991 |
BRD-M97302542-001-04-4 | ACH-000991 | SNU81_LARGE_INTESTINE | MTS010 | 1 | 1.071157 | 5.114994 | -0.08209 | 1 | 0.020404 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000991 |
BRD-A70858459-001-01-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.742991 | -0.400216 | 0.022353 | 0.942421 | 0.001567 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000994 |
BRD-A74914197-001-02-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.314424 | 5.688462 | 0.257186 | 1 | 0.038547 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000994 |
BRD-K02113016-001-19-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.987567 | -0.044513 | -0.001438 | 0.992823 | 87.75421 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000994 |
BRD-K02130563-001-11-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.108203 | 1.711653 | 0.910181 | 0.423838 | 0.018894 | 0.021787 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000994 |
BRD-K03390685-001-01-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 2.644489 | 5.384019 | 0.773764 | 1 | 1.312957 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000994 |
BRD-K03406345-001-21-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.849396 | 18.039116 | 0.106907 | 0.995507 | 7.488675 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000994 |
BRD-K03449891-001-08-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.332094 | -0.234091 | -0.004074 | 1 | 0.004366 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000994 |
BRD-K03765900-001-01-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.043722 | 0.268539 | -0.00123 | 1 | 1.909447 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000994 |
BRD-K05804044-001-18-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.136529 | -1.850733 | -0.040081 | 1 | 118.583501 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000994 |
BRD-K06814349-304-02-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.73856 | 6.640422 | 0.361453 | 0.868677 | 0.076375 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000994 |
BRD-K08109215-001-06-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.715679 | 0.617473 | 0.2569 | 0.867812 | 0.11381 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000994 |
BRD-K08542803-001-02-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.06508 | 8.399766 | 0.810211 | 0.709497 | 0.490227 | 0.498424 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000994 |
BRD-K08547377-001-04-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.563639 | 1.697173 | 0.401909 | 0.909912 | 1.375775 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000994 |
BRD-K08703257-001-13-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.033912 | -0.076746 | -0.002657 | 1 | 2,453.564195 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000994 |
BRD-K08799216-001-05-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | -0.541033 | 3.123896 | 0.469641 | 0.968966 | 2.818436 | 2.228716 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000994 |
BRD-K09951645-001-11-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.836605 | 0.869563 | -0.06429 | 0.867044 | 0.00285 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000994 |
BRD-K11267252-001-05-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.014275 | -0.172564 | -0.043166 | 1 | 46.97332 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000994 |
BRD-K11630072-001-13-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.254772 | 4.810904 | 0.401794 | 0.988367 | 9.8553 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000994 |
BRD-K12184916-001-19-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | -0.298141 | 0.035478 | -0.115734 | 0.51576 | 178,935.72019 | 0.337115 | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000994 |
BRD-K12343256-001-14-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 2.327996 | 5.270987 | 0.684881 | 1 | 0.038082 | null | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000994 |
BRD-K13049116-001-04-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.951395 | -0.151263 | -0.023774 | 0.966827 | 15.245537 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000994 |
BRD-K13390322-001-06-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.107905 | 3.778952 | 0.894968 | 0.763157 | 0.76042 | 0.81095 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000994 |
BRD-K13514097-001-04-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.545694 | 0.164713 | 0.005633 | 0.681658 | 0.000345 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000994 |
BRD-K13662825-001-07-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.080809 | 1.777097 | 0.745982 | 0.583527 | 0.030836 | 0.034051 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000994 |
BRD-K14109347-001-03-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | -0.068881 | 3.989768 | 0.581634 | 0.972111 | 8.695907 | 8.419088 | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000994 |
BRD-K15179879-001-03-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.092969 | 1.019058 | 0.830848 | 0.413981 | 0.018391 | 0.022505 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000994 |
BRD-K15600710-066-05-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.184883 | 9.026145 | 0.781146 | 0.722705 | 0.361622 | 0.3806 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000994 |
BRD-K16730910-001-10-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.093872 | -0.202572 | -0.03403 | 1 | 0.151623 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000994 |
BRD-K17555800-003-02-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.07689 | 0.101374 | 0.00962 | 1 | 50.53278 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000994 |
BRD-K17610631-001-03-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.559304 | 3.235658 | 0.484516 | 0.877937 | 0.658859 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000994 |
BRD-K17743125-001-08-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.059518 | 4.642182 | 0.38556 | 0.848643 | 2.097855 | 2.155926 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000994 |
BRD-K17894950-001-14-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.0812 | 0.285491 | -0.034744 | 1 | 0.010198 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000994 |
BRD-K18961567-001-01-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.942919 | 0.367642 | -0.011201 | 0.980713 | 0.757869 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000994 |
BRD-K19540840-001-09-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.314805 | -0.968905 | 0.027588 | 1 | 0.000325 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000994 |
BRD-K19687926-001-04-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.058891 | 0.037509 | -0.023103 | 1 | 229.651176 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000994 |
BRD-K19796430-001-05-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.237194 | -0.306981 | 0.096292 | 1 | 0.082996 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000994 |
BRD-K22064724-001-01-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.105494 | 13.149657 | 0.367423 | 0.780612 | 0.925342 | 0.942166 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000994 |
BRD-K22822991-001-02-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.827219 | 0.318764 | 0.056285 | 0.9268 | 0.246452 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000994 |
BRD-K23228615-001-02-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.428636 | 1.52219 | 0.539007 | 0.876814 | 1.268735 | 4.558433 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000994 |
BRD-K23984367-001-07-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.932314 | 0.157271 | -0.014638 | 0.966149 | 0.077853 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000994 |
BRD-K26026438-001-01-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.012264 | 0.056024 | -0.009305 | 1 | 0.011823 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000994 |
BRD-K26657438-001-15-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.989178 | 0.046619 | -0.010172 | 0.994413 | 0.019226 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000994 |
BRD-K28822270-001-03-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.107531 | 10.77533 | 0.825365 | 0.809664 | 1.320979 | 1.35101 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000994 |
BRD-K29905972-001-06-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.807278 | 0.848382 | 0.190442 | 0.864278 | 0.009694 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000994 |
BRD-K30577245-001-05-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.808809 | -8.453681 | 0.11155 | 0.904407 | 0.004879 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000994 |
BRD-K31698212-001-02-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.227962 | 0.11181 | 0.006791 | 1 | 0.440084 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000994 |
BRD-K31928526-001-02-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.024405 | -0.022313 | -0.004636 | 1 | 0.006954 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000994 |
BRD-K33379087-001-07-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.73514 | 0.817932 | 0.265323 | 0.855474 | 0.049271 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000994 |
BRD-K33610132-001-02-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 4.133099 | 1.197294 | 0.326876 | 1 | 35.680849 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000994 |
BRD-K33622447-066-01-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.652595 | 3.641153 | 0.387503 | 0.906685 | 0.737782 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000994 |
BRD-K35520305-001-16-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.072402 | -0.012258 | -0.000725 | 1 | 1,477,022,996,838,318,800,000,000,000 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000994 |
BRD-K36627727-001-05-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.09105 | 1.89149 | 0.157635 | 1 | 0.060749 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000994 |
BRD-K36788280-001-01-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.780524 | -0.22031 | -0.044855 | 0.952928 | 0.000133 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000994 |
BRD-K37379014-001-02-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.232318 | 0.72744 | 0.100512 | 1 | 0.006213 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000994 |
BRD-K38332599-001-01-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.832027 | 3.800246 | 0.220354 | 0.938695 | 0.289581 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000994 |
BRD-K38527262-300-01-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | -22.046214 | 1.684746 | 0.188175 | 0.951665 | 67.457499 | 7.034258 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000994 |
BRD-K38852836-001-02-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.546243 | 0.841723 | 0.385192 | 0.698352 | 0.003671 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000994 |
BRD-K39974922-001-04-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.974854 | 0.37782 | 0.001539 | 0.981403 | 0.002533 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000994 |
BRD-K41859756-001-06-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.54033 | 2.692126 | 0.598532 | 0.65727 | 0.001804 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000994 |
BRD-K42495768-001-01-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | -0.664557 | 1.790828 | 0.356297 | 0.977138 | 20.791989 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000994 |
BRD-K42805893-001-04-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.025717 | 0.149856 | -0.012596 | 1 | 0.370128 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000994 |
BRD-K42828737-001-03-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.871469 | -5.397491 | 0.043743 | 0.941537 | 0.026825 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000994 |
BRD-K43389675-001-02-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.059768 | 5.039641 | 0.759198 | 0.716916 | 0.538332 | 0.552106 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000994 |
BRD-K44227013-001-06-4 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | -0.517378 | 2.686316 | 0.408715 | 0.959733 | 10.009907 | 7.683914 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000994 |
BRD-K44408410-001-17-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.667517 | 1.297742 | 0.348611 | 0.889272 | 0.39938 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000994 |
BRD-K46386702-001-02-1 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.840366 | -2.390832 | 0.108053 | 0.899881 | 0.268351 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000994 |
BRD-K49328571-001-15-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.788787 | -0.510891 | 0.038583 | 0.939453 | 0.006078 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000994 |
BRD-K50010139-001-01-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.233394 | 1.158243 | -0.010773 | 1 | 0.011768 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000994 |
BRD-K50168500-001-07-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.092004 | 0.121371 | 0.002444 | 1 | 0.004392 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000994 |
BRD-K51313569-001-07-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.950431 | 0.72335 | 0.036023 | 0.97815 | 0.143899 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000994 |
BRD-K51791723-003-01-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.09722 | 1.027195 | 0.791327 | 0.721352 | 0.523172 | 0.645744 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000994 |
BRD-K51967704-001-03-6 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.425074 | 4.514912 | 0.68582 | 0.766073 | 0.192808 | 0.293567 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000994 |
BRD-K52313696-001-12-3 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.30122 | 0.32786 | 0.167967 | 1 | 1.365002 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000994 |
BRD-K53414658-001-08-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.613829 | 0.402804 | 0.112535 | 0.842913 | 0.262879 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000994 |
BRD-K53972329-001-07-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 8.510887 | -1.00708 | 0.061 | 1 | 0.000014 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000994 |
BRD-K54256913-001-08-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.078077 | 5.572403 | 0.762532 | 0.842778 | 1.910954 | 1.970092 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000994 |
BRD-K54955827-001-02-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.119453 | 0.016849 | -0.000419 | 1 | 0.000037 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000994 |
BRD-K54997624-001-06-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.289184 | 0.336779 | 0.20934 | 1 | 0.59932 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000994 |
BRD-K55187425-236-05-2 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.740384 | 6.128242 | 0.310903 | 0.795448 | 0.004778 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000994 |
BRD-K56343971-001-14-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.131329 | 0.165543 | -0.001617 | 1 | 49.330687 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000994 |
BRD-K56981171-001-02-8 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.780667 | -0.81751 | -0.009319 | 0.936606 | 0.008889 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000994 |
BRD-K57080016-001-15-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.978564 | 1.167043 | 0.678449 | 1 | 0.439396 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000994 |
BRD-K57169635-001-04-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.989667 | 0.596836 | -0.001397 | 0.99551 | 0.159072 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000994 |
BRD-K58435339-001-03-0 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.491273 | 2.773153 | 0.566675 | 0.666631 | 0.017303 | 0.074487 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000994 |
BRD-K58529924-001-01-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 1.032728 | -0.208534 | -0.009573 | 1 | 0.134506 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000994 |
BRD-K58550667-001-08-7 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.093198 | 3.276468 | 0.892378 | 0.651056 | 0.014926 | 0.015896 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000994 |
BRD-K59317601-001-05-5 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.458887 | 1.152088 | 0.575842 | 0.752451 | 0.118377 | 1.03518 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000994 |
BRD-K59369769-001-22-9 | ACH-000994 | HEC59_ENDOMETRIUM | MTS010 | 1 | 0.475638 | 0.421994 | 0.278049 | 0.8531 | 1.435278 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000994 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.